GlaxoSmithkline Pharmaceuticals Limited (BSE:500660) is looking to sell some of its non-core brands as the company looks to consolidate its position in the chronic and vaccine segments, according to people directly aware of the development. The move is expected to mop up around INR 1 billion for the drug maker which is seeking to accelerate growth in the competitive Indian domestic pharma space that witnessed price cuts to court rulings on the sale of certain fixed-dose combination drugs. GSK has approached FDC Pharma, Piramal Enterprises Limited (BSE:500302) and Strides Pharma Science Limited (NSEI:STAR).